Companies: Karyopharm
Drugs: Selinexor, Ruxolitinib
Karyopharm's Selinexor Plus Ruxolitinib SENTRY Trial Data to be Presented at EHA 2026
Karyopharm's Phase 3 SENTRY trial evaluating selinexor in combination with ruxolitinib for myelofibrosis has been selected for a late-breaking oral presentation at EHA 2026. This presentation will feature results from the randomized, double-blind, placebo-controlled study.
Executive Summary
- The Phase 3 SENTRY trial of selinexor plus ruxolitinib in myelofibrosis secured a late-breaking oral presentation slot at EHA 2026, meaning the EHA Scientific Program Committee ranked it among the top six abstracts submitted to the congress.
- SENTRY is a randomized, double-blind, placebo-controlled study testing 60 mg selinexor combined with ruxolitinib versus placebo plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis patients — a frontline positioning against the current standard of care.
- Top-line data were anticipated in mid-2026; the EHA presentation will deliver the first detailed public Phase 3 results, making it a binary regulatory and commercial catalyst for Karyopharm.
- A positive readout could support a supplemental regulatory filing in myelofibrosis, a market currently anchored by Incyte's Jakafi and Bristol Myers Squibb's Rebelsa but facing fragmentation from next-generation JAK inhibitors and novel mechanism agents.
- Selinexor's tolerability profile — notably nausea, fatigue, and thrombocytopenia — will be scrutinized as heavily as efficacy, given that the combination must demonstrate clear incremental benefit over ruxolitinib monotherapy to justify clinical adoption.
Market Impact
| Regulatory | high |
|---|---|
| Commercial | high |
| Competitive | medium |
| Investment | high |
Ask about this article
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
Karyopharm's SENTRY Trial Data Selected for Late-Breaking EHA 2026 Presentation
Karyopharm's Phase 3 SENTRY trial evaluating selinexor in combination with ruxolitinib for myelofibrosis has been selected for a late-breaking oral presentation at EHA 2026. The presentation will feature results from the randomized, double-blind, placebo-controlled study. The designation — reserved by the European Hematology Association's Scientific Program Committee for the six most consequential abstracts submitted — positions the readout as a pivotal catalyst for Karyopharm's expansion beyond selinexor's current multiple myeloma and DLBCL approvals into a myelofibrosis market undergoing significant competitive transition.
Key Takeaways
- The Phase 3 SENTRY trial of selinexor plus ruxolitinib in myelofibrosis secured a late-breaking oral presentation slot at EHA 2026, meaning the EHA Scientific Program Committee ranked it among the top six abstracts submitted to the congress.
- SENTRY is a randomized, double-blind, placebo-controlled study testing 60 mg selinexor combined with ruxolitinib versus placebo plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis patients — a frontline positioning against the current standard of care.
- Top-line data were anticipated in mid-2026; the EHA presentation will deliver the first detailed public Phase 3 results, making it a binary regulatory and commercial catalyst for Karyopharm.
- A positive readout could support a supplemental regulatory filing in myelofibrosis, a market currently anchored by Incyte's Jakafi and Bristol Myers Squibb's Rebelsa but facing fragmentation from next-generation JAK inhibitors and novel mechanism agents.
- Selinexor's tolerability profile — notably nausea, fatigue, and thrombocytopenia — will be scrutinized as heavily as efficacy, given that the combination must demonstrate clear incremental benefit over ruxolitinib monotherapy to justify clinical adoption.
Why Did EHA Rank SENTRY Among Its Six Best Abstracts?
Karyopharm announced on June 2, 2026, that the SENTRY abstract had been selected for a late-breaking oral presentation at the European Hematology Association Congress. The late-breaking track at EHA is not a promotional category; the Scientific Program Committee reserves it for data expected to alter clinical practice or meaningfully advance disease understanding. Only six abstracts earn this designation from the full submission pool.
The SENTRY trial is a global, multicenter, randomized, double-blind, placebo-controlled study evaluating 60 mg of selinexor plus ruxolitinib versus placebo plus ruxolitinib in patients with JAK inhibitor treatment-naïve myelofibrosis. Full trial details are registered on ClinicalTrials.gov. The design reflects a deliberate strategy: rather than positioning the combination in later-line patients who have failed JAK inhibitor therapy, Karyopharm is testing whether adding selinexor's XPO1 inhibition to ruxolitinib's JAK1/2 blockade can improve outcomes in the frontline setting, where ruxolitinib alone remains standard.
The scientific rationale rests on complementary mechanisms. Ruxolitinib reduces spleen volume and alleviates constitutional symptoms through JAK-STAT pathway inhibition but does not consistently modify underlying disease biology. Selinexor, a selective inhibitor of nuclear export, forces nuclear retention of tumor suppressor proteins including p53, Rb, and p27. Preclinical and early clinical data supporting this combination approach have been published and are accessible via PubMed Central. Whether this mechanistic synergy translates into clinically meaningful benefit over ruxolitinib alone is the central question the Phase 3 data must answer.
How Could SENTRY Reshape the Myelofibrosis Treatment Market?
The myelofibrosis market is in active flux. Incyte's ruxolitinib (Jakafi) has anchored frontline therapy for over a decade, but its revenue trajectory faces pressure from patent erosion and an increasingly crowded competitive field. Bristol Myers Squibb's fedratinib (Rebelsa) and the JAK2 inhibitor momelotinib (Ojjaara) have established niches, while CTI Biopharma's pacritinib (Vonjo) serves the thrombocytopenic subgroup. Novartis, GSK, and several biotechs are advancing next-generation agents — including BET inhibitors and BCL-2 family inhibitors — through late-stage development.
Karyopharm's approach is structurally different from most competitors. Rather than developing a next-generation JAK inhibitor, the company is layering a novel nuclear export inhibition mechanism onto the existing standard. If SENTRY demonstrates meaningful improvements in spleen volume reduction, symptom scores, or — more ambitiously — bone marrow fibrosis grade or overall survival, the combination could establish a first-line positioning that disrupts the current treatment paradigm. If the data show only marginal incremental benefit, the commercial case becomes difficult to sustain, particularly given selinexor's known gastrointestinal and hematologic toxicity profile and the availability of better-tolerated alternatives in development.
For business development teams, the EHA presentation will clarify whether selinexor plus ruxolitinib warrants partnership interest or competitive monitoring. A compelling data set could elevate Karyopharm's profile as a potential acquisition target or licensing partner for larger oncology companies seeking differentiated myelofibrosis assets. A lukewarm readout would likely reinforce the prevailing industry view that selinexor's toxicity constraints limit its utility to hematologic malignancies with fewer therapeutic alternatives.
What Should Investors and Analysts Watch For at EHA 2026?
The presentation will be dissected across multiple efficacy and safety dimensions. Spleen volume reduction at 24 or 36 weeks is the most probable primary endpoint, consistent with prior myelofibrosis registrational trials. Total symptom score improvement, transfusion independence rates, and the frequency of dose reductions or discontinuations due to adverse events will all factor into the market's assessment. Analysts will also look for any signal on bone marrow fibrosis improvement or molecular response — endpoints that would meaningfully differentiate the combination from JAK inhibitor monotherapy and suggest disease modification rather than symptomatic control.
Karyopharm's corporate materials have indicated that top-line SENTRY data were expected in mid-2026, with a regulatory submission contingent on positive results. The company's investor disclosures, filed with the SEC, outline the development timeline. The absence of a pre-presentation press release with headline numbers means the market is approaching this event with limited visibility, amplifying the potential for a volatile post-presentation share price move.
From a valuation standpoint, Karyopharm's current market capitalization reflects the binary nature of this catalyst. A positive readout supporting a regulatory filing within 12 to 18 months could trigger a meaningful re-rating, particularly if the data suggest a competitive advantage in the large JAK inhibitor-naïve population. A negative or ambiguous result would likely pressure the stock and raise fundamental questions about selinexor's pipeline potential beyond its currently approved indications.
Frequently Asked Questions
What does the late-breaking designation mean for the SENTRY data?
The EHA Scientific Program Committee selects only six abstracts for the late-breaking oral presentation track at each congress. This designation indicates the committee judged the SENTRY Phase 3 data to be among the most clinically and scientifically significant findings submitted to EHA 2026 — a strong signal, though the actual efficacy and safety results will determine the ultimate impact.
Which patients does the SENTRY trial enroll?
SENTRY evaluates selinexor plus ruxolitinib in patients with myelofibrosis who are JAK inhibitor (JAKi) treatment-naïve — meaning they have not previously received any JAK inhibitor therapy. This frontline positioning is designed to test whether the combination can outperform ruxolitinib monotherapy as an initial treatment regimen. The full protocol is available on ClinicalTrials.gov.
What is selinexor's current approved use, and how does myelofibrosis fit?
Selinexor (marketed as Xpovio) is FDA-approved in combination with bortezomib and dexamethasone for previously treated multiple myeloma and with dexamethasone for relapsed or refractory diffuse large B-cell lymphoma. Myelofibrosis would represent a new therapeutic indication. The preclinical and early clinical rationale for combining selinexor with ruxolitinib has been published and is accessible via PubMed Central.
What are Karyopharm's next steps after the EHA presentation?
Karyopharm has indicated that a regulatory submission for the selinexor plus ruxolitinib combination in myelofibrosis is contingent on positive Phase 3 SENTRY data. If the EHA results support a filing, the company would likely pursue a supplemental NDA, with potential commercialization within 12 to 18 months of a successful submission.
How does this combination approach compete with other myelofibrosis therapies in development?
Unlike most pipeline programs that target next-generation JAK inhibition or single novel mechanisms, Karyopharm is combining an approved JAK inhibitor with a nuclear export inhibitor. The SENTRY data will determine whether this dual-mechanism strategy delivers clinically meaningful advantages over both existing JAK inhibitor monotherapy and emerging agents — including BET inhibitors, BCL-2 inhibitors, and other novel compounds advancing through late-stage myelofibrosis trials.
Related profiles
Related coverage
This article follows our editorial standards. Report a correction via editorial contact.
